ReviewESMO open2022
The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer.
S Michaleas et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
15 papers cite it
this papertrialcites it